Examples of using An interaction study in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
In an interaction study, tolcapone did not change the pharmacokinetics of tolbutamide.
Cholestagel had no effect on the bioavailability of lovastatin in an interaction study.
In an interaction study, the mean doripenem AUC increased by 75% following co-administration with probenecid.
No pharmacokinetic or pharmacodynamic interaction with cangrelor was observed in an interaction study with aspirin, heparin, or nitroglycerin.
In an interaction study of single-dose bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was increased by 22%.
The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinalproducts causing these effects, for example beta blockers, although additional effects in an interaction study with esmolol were modest.
Results from an interaction study with Kaletra and pravastatin reveal no clinically significant interaction. .
An interaction study with protein-conjugated vaccine against Neisseria menigitidis serogroup C has been investigated in children aged 2-11 years.
When fingolimod was used with atenolol in an interaction study in healthy volunteers, there was an additional 15% reduction of heart rate at fingolimod treatment initiation, an effect not seen with diltiazem.
An interaction study with carbamazepine does not indicate a marked inhibitory effect of lacosamide on CYP3A4 catalysed metabolism at therapeutic doses.
Effects of lamotrigine on hormonal contraceptive efficacy An interaction study in 16 healthy volunteers has shown that when lamotrigine and a hormonal contraceptive(ethinyloestradiol/ levonorgestrel combination) are administered in combination, there is a modest increase in levonorgestrel clearance and changes in serum FSH and LH(see section 4.5).
In an interaction study, Prolia did not affect the pharmacokinetics of midazolam, which is metabolized by cytochrome P450 3A4(CYP3A4).
Based on an interaction study with lopinavir/ ritonavir, combination of rosuvastatin and protease inhibitors is not recommended.
In an interaction study in healthy volunteers, Cholestagel reduced the AUC and Cmax of levothyroxine when administered either concomitantly or after 1 hour.
In an interaction study of single-dose bedaquiline and multiple-dose lopinavir/ritonavir, exposure(AUC) to bedaquiline was increased by 22%[90% CI(11; 34)].
In an interaction study, the serum concentrations of valproic acid were markedly reduced(AUC was reduced by 63%) following co-administration of doripenem and valproic acid.
In an interaction study in healthy volunteers, co-administration of Cholestagel and ciclosporin significantly reduced the AUC0-inf and Cmax of ciclosporin by 34% by 44%, respectively.
However, in an interaction study in healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R-warfarin increased on average by 18%[CI90 11- 26%].
However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R- warfarin increased on average by 18%[CI90 11-26%].
An interaction study in women between APTIVUS, co-administered with low dose ritonavir, and ethinyl oestradiol/ norethindrone demonstrated a high frequency of non-serious rash.
In an interaction study based on data from 17 patients, assessing the effect of omeprazole, a potent CYP2C19 inhibitor, there was no significant effect on the pharmacokinetics of bortezomib.
An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors.
An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed increased plasma concentrations of bosentan, with the maximum level during the first 4 days of treatment(see section 4.5).
An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin Cmax increased by 15% and AUC increased by 59% following co- administration.
In an interaction study of single-dose bedaquiline and once daily rifampicin(strong inducer) in healthy subjects, the exposure(AUC) to bedaquiline was reduced by 52%[90% CI(-57; -46)].
An interaction study based on data from 12 patients, assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, showed a bortezomib AUC mean increase of 35%(CI90%[1.032 to 1.772]).
Data from an interaction study involving Vectibix and irinotecan in patients with mCRC indicated that the pharmacokinetics of irinotecan and its active metabolite, SN-38, are not altered when the medicinal products are co-administered.
In an interaction study conducted in healthy subjects with multiple doses of Zurampic 400 mg and single dose warfarin(25 mg), lesinurad led to a decrease in exposure of R-warfarin(the less active enantiomer) and had no effect on the exposure of S-warfarin(the more active enantiomer).
In an interaction study with healthy volunteers, co-administration of clopidogrel(300 mg loading dose),a CYP2C8 inhibitor, increased repaglinide exposure(AUC0-∞) 5.1-fold and continued administration(75 mg daily dose) increased repaglinide exposure(AUC0-∞) 3.9-fold.
In an interaction study in healthy volunteers, co- administration of 250 mg clarithromycin,a potent mechanism-based inhibitor of CYP3A4, slightly increased the repaglinide(AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold.